English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

According to the recent National Comprehensive Cancer Network (NCCN) guidelines, the risk level in acute myeloid leukemia (AML) patients with  and  double mutation (AML  ) depends on the allelic ratio of . But despite a low or high allelic ratio of , AML  patients belong to the favorable or intermediate risk, for whom allogeneic stem cell transplantation is not obligated. However, some latest studies pointing out that  and  double mutation patients showed an inferior prognosis, which have raised concern about the risk categorization and more effective treatment of AML  patients.  A total of 76 patients were selected for coexisting  and  mutations with normal cytogenetics. The prognostic risk factors were analyzed, and treatment strategies including allogeneic stem cell transplantati1on and chemotherapy were compared.  In 76 AML  patients, 36.8% of patients had hyperleukocytosis (HL) and  mutation was the most common concomitant gene (23.7%). For 53 patients in the complete remission (CR), 22 had received allogeneic hematopoietic stem cell transplantation (allo-HSCT) on first complete remission (CR1). Patients in transplantation group had better overall survival (OS) and disease-free survival (DFS) than chemotherapy only (=0.002 and 0.001, respectively). In multivariable Cox model analyses, HL and  mutation were independent adverse prognostic factors (all <0.05) for AML  patients. Nevertheless, allo-HSCT was an independent good factor of OS and DFS (=0.001 and 0.000; HR =0.173 and 0.138; 95% CI were 0.062-0.483 and 0.049-0.389). And allo-HSCT could moderately improve the poor prognosis of AML   Although, AML  patients are categorized as favorable or intermediate risk levels according to recent NCCN and ELN guidelines, these patients should receive allo-HSCT in CR1 for a longer survival. AML  patients with  mutation had a very poor prognosis, and allo-HSCT could moderately improve their survival.

cancer management and research

&lt;p&gt;Acute myeloid leukemia patient with &lt;em&gt;FLT3-ITD&lt;/em&gt; and &lt;em&gt;NPM1&lt;/em&gt; double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis &lt;/p&gt;